Induced-volatolomics for the design of tumour activated therapy
Rémi Châtre(Centre National de la Recherche Scientifique), Estelle Blochouse(Centre National de la Recherche Scientifique), Rony Eid(Centre National de la Recherche Scientifique), Fabiola Djago(Centre National de la Recherche Scientifique), Justin Lange(Centre National de la Recherche Scientifique), Mehrad Tarighi(Centre National de la Recherche Scientifique), Brigitte Renoux(Centre National de la Recherche Scientifique), Julien Sobilo(Centre National de la Recherche Scientifique), Alain Le Pape(Centre National de la Recherche Scientifique), Jonathan Clarhaut(Centre National de la Recherche Scientifique), Claude Geffroy-Rodier(Centre National de la Recherche Scientifique), Isabelle Tranoy‐Opalinski(Centre National de la Recherche Scientifique), Wei Tuo(Centre National de la Recherche Scientifique), Sébastien Papot(Centre National de la Recherche Scientifique), Pauline Poinot(Centre National de la Recherche Scientifique)
Cited by 9Open Access
Abstract
-acetylglucosaminidase was a hallmark of several solid tumours. Having identified this glycosidase as a potential target for cancer therapy, we designed an enzyme-responsive albumin-binding prodrug of the potent monomethyl auristatin E programmed for the selective release of the drug in the tumour microenvironment. This tumour activated therapy produced a remarkable therapeutic efficacy on orthotopic triple-negative mammary xenografts in mice, leading to the disappearance of tumours in 66% of treated animals. Thus, this study shows the potential of induced-volatolomics for the exploration of biological processes as well as the discovery of novel therapeutic strategies.
Related Papers
No related papers found
Powered by citation graph analysis